Although it could be a modest increase in the risk, a better stratification of the patients according to the DDIT4 expression or stratification according other clinic or molecular features could enhance the DDIT4 value as prognostic biomarker; for example in our work, DDIT4 overexpression in breast cancer was highly related with the recurrence in the basal subtype (P = 3.8 × 10−7) while it had not prognostic value in the HER2-enriched subtype (Fig. 2). This evidence concerns the gene DDIT4 and breast cancer.